Tocilizumab plus chemoimmunotherapy for advanced colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of medications for people with locally advanced colon cancer. It aims to see if adding tocilizumab to standard chemo-immunotherapy can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colon cancer that has not been treated yet.
- Your tumor is at least 10 cm away from your anus.
- You are between 18 and 80 years old.
- You are in generally good health (able to do normal daily activities).
- You do not have active infections or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests whether a stronger chemo combination plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemo alone when given before surgery for locally advanced colon cancer. It aims to shrink the tumor and improve outcomes.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.